Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the fourth quarter and year ended December 31, 2012.

Three months ended December 31, 2012
For the three months ended December 31, 2012, Orexigen reported a net loss of $32.5 million, or $0.41 per share, as compared to a net loss of $4.3 million, or $0.09 per share, for the fourth quarter of 2011.

Total operating expenses for the fourth quarter of 2012 were $33.3 million compared to $5.2 million for the fourth quarter of 2011. This overall increase in operating expenses reflects an increase in research and development expenses associated with the conduct of the Light Study, the Contrave® cardiovascular outcomes trial.

Year ended December 31, 2012
For the year ended December 31, 2012, Orexigen reported a net loss of $90.1 million, or $1.27 per share, as compared to a net loss of $28.1 million, or $0.58 per share, for 2011.

Total operating expenses for 2012 were $93.7 million compared to $32.3 million for 2011. This overall increase in operating expenses reflects an increase in research and development expenses associated with the conduct of the Light Study.

As of December 31, 2012, Orexigen had $78.3 million in cash and cash equivalents and an additional $59.1 million in marketable securities, for a total of $137.4 million. Cash burn for 2013 is projected to be between $70 million and $85 million with total burn dependent on the timing of the Light Study interim analysis and associated pre-launch expenses.

"I am extremely proud of the work our team accomplished in 2012 to expedite enrollment of the Light Study, and our focus is now on 2013 which has the potential to be a pivotal year for Orexigen," said Michael Narachi, CEO of
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Fruit Street Health ... initial seed round of funding. The ... by a series of individual investors, the majority of ... in the initial round are; Houston Cardiology Consultants ... Urologist Stacy Childs, Rapha Family Medicine Practice Owner ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... 31, 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd ... clinical study to confirm the efficacy of its novel ... trial is evaluating the efficacy, safety and tolerability of ... compared to vehicle. The trial consists of treating 132 ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... BSTC ), a biopharmaceutical company, today announced ... Companies and announced plans to move XIAFLEX forward in ... as well as to collaborate on the initiation of ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 2Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 3Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 4Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 5Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 6Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 7Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX® 8
(Date:9/18/2014)... 18, 2014 It is that time of ... and wellness. Once again, Evensong Spa at ... offering three services at a special $50 rate Oct. 20 ... Marcus Hotels & Resorts , is the only Wisconsin ... Americans to embrace health and wellness by experiencing affordable spa ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... is good for you. But new research from University ... added benefit for cancer patients undergoing chemotherapy. , Their ... that combining exercise with chemotherapy shrunk tumors more than ... in the School of Nursing and director of the ... senior author on the study, which appears in the ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 2014 Thousands of college and high ... shared fundraising impact on 127 member Children’s Miracle ... first-ever Dance Marathon Day will officially kick off a ... be raised by college and high school students funding ... through Dance Marathon campus programs help provide medical equipment, ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... Multiple approaches are found to boost success of people ... -- To truly help people quit smoking, doctors need ... might require repeated or intensive interventions, including pharmacotherapy and ... 750 people who smoked at least 10 cigarettes a ...
... April 8 Dialysis Corporation of America (Nasdaq: ... into a grant agreement with the University of ... $265,000 each year, for the next three years, will ... clinical research relating to kidney disease. This multi-year agreement ...
... much less nausea while receiving radiation treatment, making the ... to a study published in the Journal of ... Medical Center researchers. , Previous research has suggested ... to your body that you expect to happen ...
... Individuals How Much They Will Pay for Treatment ... Their HealthcareANN ARBOR, Mich., April 8 As ... its cost, employers and health insurers need better ... well-informed decisions about their health and use of ...
... community of hope. PHILADELPHIA, April 8 Kyle,s Treehouse ... announces their new initiative for Autism Awareness Month: Autism151, ... Autism151 focuses on the positive side of the autism ... stories of strength, inspiration and success with one another, giving ...
... State Tobacco Prevention ProgramsCOLUMBUS, Ohio, April 8 ... tobacco and flavored little cigars - are addictive and ... rate as cigarettes in Ohio, according to a radio ... health organizations.(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ...
Cached Medicine News:Health News:Doctors Urged to Get Aggressive to Help Smokers 2Health News:Dialysis Corporation of America Announces Establishment of Clinical Grant Agreement with the University of Cincinnati, College of Medicine 2Health News:Wristbands ease nausea with cancer treatment 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 2Health News:HealthEquity, a Leading Healthcare Account Administrator, Licenses Thomson Reuters Information Solutions to Help People Make Better Healthcare Decisions 3Health News:Kyle's Treehouse Launches Autism151.com for Autism Awareness Month 2Health News:New Ohio Ad Campaign Calls for Taxing All Tobacco Products at Same Rate 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: